Literature Review Recognizes Ahiflower® Oil As Sustainable Alternative to Marine Omega-3’s

January 15, 2024 12:00 PM GMT | By EIN Presswire
 Literature Review Recognizes Ahiflower® Oil As Sustainable Alternative to Marine Omega-3’s
Image source: EIN Presswire

Ahiflower’s fatty acid profile drives growing evidence of its anti-inflammatory activity

WINSTON SALEM, NC, UNITED STATES, January 15, 2024 /EINPresswire.com/ -- In a new scientific literature review titled “Alternative sources of bioactive omega-3 fatty acids: what are the options?” and published in Current Opinion in Clinical Nutrition and Metabolic Care (CO-CN), UK lipid researcher Dr. Ella Baker, PhD addresses widely recognized concerns on the sustainability of marine omega-3 sources.

The driving premise behind this new peer-reviewed article is that traditional sources of VLC-PUFA — very long-chain polyunsaturated fatty acids, namely EPA and DHA — are no longer sustainable. This is true for fish oil-derived supplements, highly concentrated pharmaceuticals, and enteral/parenteral emulsions used in medical nutrition, and for aquaculture feeds. Dr. Baker cites that 1.25 million metric tons of fish oil was produced in 2022 with corresponding EPA/DHA production of 160,000 metric tons. About half of global fish oil production came from wild-harvested or farmed whole fish, the other half coming from fish by-products. Yet the recent Peruvian fishery closures and other omega-3 supply chain disruptions are causing the industry to make strategic shifts in sourcing.

As Dr. Baker describes meeting total omega-3 EPA/DHA demand and satisfying recommended EPA/DHA intakes globally, “This demand may not be met because of insufficient fisheries catch due to reduction in fish stocks from overfishing and climate change. Hence alternative sources of EPA and DHA to fish need to be seriously considered and their potential explored.”

Her article presents three alternative categories of direct omega-3 sources that do not involve wild-harvesting and processing oily forage fish from the oceans — typically anchovies, sardines, herring, or menhaden. Plant-based Ahiflower oil from Natures Crops, with the highest combined omega-3 SDA and GLA content, is featured in the article along with microalgae-derived EPA/DHA sources and genetically modified canola or camelina seed sources. The algal and GMO terrestrially farmed sources of pre-formed EPA/DHA were recognized for their capacity to mimic many of the recognized health benefits of fish oil supplementation.

However, this is the first omega-3 metabolism literature review article recognizing recent scientific publications describing Ahiflower oil’s differential effects and metabolic fate vs EPA/DHA sources. Among those cited:

• Likely novel anti-inflammatory oxylipins derived from SDA (vs those from EPA/DHA alone)
• Human evidence of dose-dependent increases in circulating SDA, ETA (C20:4n-3), and EPA—a wider array than occurs from EPA/DHA sources
• Production of anti-inflammatory cytokine IL-10 in humans and mice — higher than when compared to soya or fish oil
• Recognized beneficial effects on bio-markers of whole-body and hepatic glucose metabolism, immune cells, lipid mediators and intestinal microbiota.

Of the latter finding, in a 7-day intervention using total parenteral nutrition (TPN) emulsions in mice, Dr. Baker wrote, “Remarkably, the effects of the Ahiflower oil containing lipid emulsion were greater than those of the fish oil emulsion.” This included higher IL-10 and a higher IL-10/IL-6 ratio in liver and muscle, greater hepatic insulin receptor 2 expression, higher percentages of liver helper T cells expressing interferon-gamma, and elimination of a microinvasive bacterium from the gut mucosa.

Taken as a whole, Dr Baker concluded, “SDA has qualitatively similar effects to EPA and
combinations of EPA and DHA, but these are greater than the effects of ALA (at the same intake level). Recent experimental studies with oil from a commercially grown crop that is rich in SDA, Ahiflower oil, have reported remarkable effects which might result from its high content of ALA, SDA and GLA.”

This review’s recognition of Ahiflower oil’s beneficial and different health-promoting effects stemming from its uniquely high levels of ALA, SDA, and GLA augments recently published findings that Ahiflower oil matches pure marine DHA in rates of replacing and deploying new DHA into liver, adipose, and brain tissues in mice, despite not raising circulating DHA levels. Both these peer-reviewed articles point to Ahiflower oil’s capacity to efficiently form as much EPA and DHA as and when needed — naturally and dynamically — to support cell membranes and tissues. In so doing, Ahiflower oil can indeed help overcome omega-3 deficiencies causing many negative health and epidemiological outcomes, yet from a regeneratively-farmed, non-genetically modified, and wholly sustainable source.

Articles Referenced:
Current Opinion in Clinical Nutrition and Metabolic Care (DOI:10.1097/MCO.0000000000001006)
Ella J. Baker, School of Human Development and Health, Faculty of Medicine, University of Southampton

BBA — Molecular and Cell Biology of Lipids
(DOI:10.1016/j.bbalip.2023.159422)
Adam H. Metherel, Department of Nutritional Sciences, University of Toronto

###

About Natures Crops International
A manufacturer of specialty oils for dietary supplements, nutraceuticals, food, personal care and animal nutrition products, Natures Crops produces oils from the highest quality crops, produced by growers who follow strict management protocols for sustainability and identity preservation. Natures Crops ensures the crops produced are grown, processed, packaged, and delivered in a safe, sustainable, traceable, and cost-competitive manner. The company has operations in Prince Edward Island, Canada and the United Kingdom, with headquarters in North Carolina. For more information, please write to [email protected].

Jacqueline Rizo
Natures Crops International
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
Instagram
YouTube


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next